Inclusion Criteria:

• Patient has histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are excluded.
• Male or non-pregnant and non-lactating female, and age greater or equal to 18.
• If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (B-hCG)documented within 72 hours of the first administration of study drug.
• If sexually active, the patient must agree to use contraception considered adequate and appropriate by the investigator.
• Patient must have received no prior therapy for the treatment of metastatic disease. Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed. If a patient received gemcitabine in the adjuvant setting, tumor recurrence must have occurred at least 6 months after completing the last dose of gemcitabine.
• Patient has the following blood counts at baseline
• ANC equal or greater to 1.5 x 10^9/L;
• Platelets equal or greater to 100 x 10^9/L
• Hgb equal or greater to 9g/dL.
• Patient has the following blood chemistry levels at baseline:
• AST (SGOT), ALT (SGPT)equal or less than 2.5 x upper limit of normal range (ULN)is allowed
• Bilirubin less than or equal to ULN
• Serum creatinine within normal limits or calculated clearance equal or greater to 60 mL/min/1.73M^2 patients with serum creatinine levels above the institutional normal value
• Patient has no clinically significant abnormalities in urinalysis results
• Patient has acceptable coagulation status as indicated by a PT within normal limits (plus or minus 15%) and PTT within normal limits (plus or minus 15%).
• Patient has acceptable coagulation status as indicated by a PT within normal limits (plus or minus 15%).
• Patient has a Karnofsky performance status (KPS) greater or equal to 70 (ECOG PS 0-1).
• Patient has one or more metastatic tumors measurable by CT scan.
• Patient has been informed about the nature of study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities.

Exclusion Criteria:

• Patient has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids and stable in two scans at least 4 weeks apart).
• Patient uses therapeutic coumadin for a history of pulmonary emboli and deep vein thrombosis (DVT).
• Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
• Patient has known infection with HIV, hepatitis B, hepatitis C.
• Patient has undergone major surgery, other than diagnostic surgery (i.e.--) done to obtain a biopsy for diagnosis without removal of an organ), with 4 weeks prior to Day 1 of treatment in this study.
• Patient received radiotherapy, surgery, chemotherapy, or an investigational therapy within 3 weeks prior to study entry weeks (6 weeks for nitrosureas or mitomycin C).
• Patient has a history of allergy or hypersensitivity to the study drug.
• Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.
• Patient is unwilling or unable to comply with study procedures.
• Patient is enrolled in any other clinical protocol or investigational trial.